CUDC-427

Cat. No. M10811

All AbMole products are for research use only, cannot be used for human consumption.

Synonym:

GDC-0917

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.

CUDC-427 (GDC-0917) is a highly effective IAP inhibitor commonly used in research on a variety of cancers.

Molecular Weight	564.7
Formula	C29H36N6O4S
CAS Number	1446182-94-0
Solubility (25°C)	DMSO ≥ 60 mg/mL
Storage	Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month

Related IAP Products
AT-406 Xevinapant (Debio1143,AT-406, SM-406) is a potentially first-in-class, highly potent oral antagonist of inhibitor of apoptosis protein (IAP), which not only promotes cancer cell death by inhibiting IAP, but also It can enhance the anti-tumor immune response by inhibiting IAP.
GDC-0152 GDC-0152 is a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins with potential antineoplastic activity.
Birinapant Birinapant (TL32711) is a bivalent Smac analogue, which is a potent antagonist of XIAP and cIAP1 with Kd values of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces autoubiquitination and proteasome degradation of cIAP1 and cIAP2 in intact cells, resulting in the formation of RIPK1: Caspase-8 complex, which activates and induces tumor cell death.
BV6 BV6 is a small molecule Smac analog that antagonizes cIAP1 and XIAP.
LCL161 LCL161 is an orally bioavailable SMAC mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP). LCL161 enhanced the proapoptotic effects of nilotinib and PKC412, against leukemic disease in vitro and potentiated the activity of both kinase inhibitors against leukemic disease in vivo.

Catalog